The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug candidates, of which one drug candidate is in Phase III stage of development, while seven drug candidates are in Phase II stage, four drug candidates are in Phase I stage, five drug candidates are in Pre-Clinical stage and one drug candidate is in the Discovery stage.

1. GLOBAL INDUSTRY INSIGHT:
Oral Mucositis Therapeutics Pipeline Analysis, 2017 - Clinical Trials &
Results, Patent, Designation, Collaboration, and Other Developments

2. Oral Mucositis Therapeutics Pipeline to Witness Many
Technological Advancements in the Coming Years
The study analyzed that the oral mucositis therapeutics pipeline comprises approximately 18 drug
candidates, of which one drug candidate is in Phase III stage of development, while seven drug
candidates are in Phase II stage, four drug candidates are in Phase I stage, five drug candidates
are in Pre-Clinical stage and one drug candidate is in the Discovery stage. Oral mucositis is the
most common complication of chemotherapy in cancer patients. It causes damage to mucosal
lining of the mouth which results in formation of ulcers. It can result in several problems that
includes severe pain in mouth, nutritional problems as a result of inability to eat and increased risk
of infection due to open sores in the mucosa.
Access Report Overview: https://www.psmarketresearch.com/market-analysis/oral-mucositis-
therapeutics-pipeline-analysis
As per the findings of the research, around 39.0% drug candidates of oral mucositis pipeline are
being developed to be administered by topical route, 17.0% are being developed to be
administered by oral route, 17.0% are being developed to be administered by intravenous route
and 5.0% by subcutaneous route. Route of administration of around 22.0% drug candidates of oral
mucositis pipeline is not disclosed.
Oragenics, Inc. is using ActoBiotics technology platform for the development of AG 013 for the
treatment of oral mucositis. The technology platform produces a new class of orally delivered
biopharmaceuticals. Through ActoBiotics technology platform, food-grade microbes are engineered
to generate biologically contained ActoBiotics therapeutics for in situ expression and secretion of
novel proteins and peptides including cytokines, enzymes, hormones and monoclonal antibodies
within the body. The ActoBiotics platform offers the ability to deliver biological effectors selectively
to the oral and gastrointestinal tract enabling treatment opportunities not achievable through
customary mechanisms such as injectable medicines and permitting ease of administration for
patients. With intervention focused at the site of pathology, the ActoBiotic's biopharmaceuticals has
the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and
autoimmune diseases.
Explore Report Sample at: https://www.psmarketresearch.com/market-analysis/oral-mucositis-
therapeutics-pipeline-analysis/report-sample
The research also found that various companies received designations from the USFDA for the
development of the drugs in the oral mucositis therapeutics pipeline. In November 2016, USFDA
granted Fast Track designation to AG013 for the treatment of oral mucositis. In November 2015,
USFDA granted Fast Track designation to Brilacidin for the treatment of oral mucositis.
© P&S Market Research. All rights reserved 2

3. Oral Mucositis Therapeutics Pipeline to Witness Many
Technological Advancements in the Coming Years
Many companies are involved in the development of drugs for the oral mucositis therapeutics
pipeline, with their products in different phases. Daewoong Pharmaceutical Co., Ltd. has its drug
candidates in the Phase III stage of development. Cellceutix Corporation, Onxeo S.A. and Novartis
AG have their drug candidates in the Phase II stage of development. Galera Therapeutics, Inc. has
two drug candidates each in Phase II and Phase I stage of development. Oragenics, Inc. has one
drug candidate in Discovery stage of development.
Pre-Purchase Enquiry at: https://www.psmarketresearch.com/send-enquiry?enquiry-url=oral-
mucositis-therapeutics-pipeline-analysis
Some of the other key players developing drugs for the treatment of oral mucositis include
Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc., Onxeo S.A., Novartis
AG, TFS Corporation, Izun Pharmaceuticals Corp., Oragenics, Inc., Wellstat Therapeutics
Corporation, Otsuka Holdings Co., Ltd. and Galera Therapeutics, Inc.
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline analysis by phase
1.3.2 Pipeline analysis by target
1.3.3 Pipeline analysis by route of administration
1.3.4 Pipeline analysis by molecule type
1.4 Key Stakeholders
Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of primary research respondents
2.2.1.1 By industry participant
2.2.1.2 By company type
© P&S Market Research. All rights reserved 3

4. Oral Mucositis Therapeutics Pipeline to Witness Many
Technological Advancements in the Coming Years
Chapter 3. Executive Summary
Chapter 4. Pipeline Outlook
4.1 Overview
4.2 Key Drivers
4.2.1 Technical advancements
4.2.2 Use of promising targets
4.3 Key Barriers
4.3.1 Safety concerns
4.4 Oral Mucositis Pipeline Analysis
4.4.1 Pipeline analysis by phase
4.4.2 Pipeline analysis by target
4.4.3 Pipeline analysis by route of administration
4.4.4 Pipeline analysis by molecule type
4.4.5 Pipeline analysis by company
Chapter 5. Oral Mucositis Pipeline Analysis by Phase (2017)
5.1 Phase III
5.1.1 Nepidermin
5.1.1.1 Clinical trials
5.2 Phase II
5.2.1 Brilacidin
5.2.1.1 Clinical trials
5.2.1.2 Strategic development
5.2.1.3 Designation
5.2.2 Clonidine
5.2.2.1 Clinical trials
5.2.2.2 Strategic development
© P&S Market Research. All rights reserved 4

5. Oral Mucositis Therapeutics Pipeline to Witness Many
Technological Advancements in the Coming Years
5.2.2.3 Designation
5.2.2.4 Patent
5.2.2.5 Technology
5.2.3 Dexamethasone
5.2.3.1 Clinical trials
5.2.4 Dusquetide
5.2.4.1 Clinical trials
5.2.4.2 Strategic development
5.2.4.3 Designation
5.2.4.4 Grant
5.2.4.5 Patent
5.2.4.6 Technology
5.2.5 GC 4419
5.2.5.1 Clinical trials
5.2.5.2 Designation
5.2.5.3 Financing
5.2.5.4 Patent
5.2.6 Rebamipide
5.2.6.1 Clinical trials
5.2.7 Sandalwood Album Oil (SAO)
5.2.7.1 Clinical trials
5.2.7.2 Strategic development
5.3 Phase I
5.3.1 AG 013
5.3.1.1 Clinical trials
5.3.1.2 Clinical results
© P&S Market Research. All rights reserved 5

6. Oral Mucositis Therapeutics Pipeline to Witness Many
Technological Advancements in the Coming Years
5.3.1.3 Strategic development
5.3.1.4 Designation
5.3.1.5 Grant
5.3.1.6 Financing
5.3.1.7 Technology
5.3.2 GC 4702
5.3.2.1 Clinical trials
5.3.2.2 Financing
5.3.3 IZN 6N4
5.3.3.1 Clinical trials
5.3.4 Melatonin
5.3.4.1 Clinical trials
5.4 Pre-Clinical
5.4.1 ADX-102
5.4.1.1 Technology
5.4.2 BCD 600 Biobetter
5.4.3 Bupivacaine
5.4.3.1 Strategic development
5.4.3.2 Grant
5.4.3.3 Technology
5.4.4 CVXL-0095
5.4.5 WT621
5.5 Discovery
5.5.1 Oral Cavity Disorder Biotherapeutics
5.5.1.1 Strategic development
5.5.1.2 Technology
© P&S Market Research. All rights reserved 6

7. Oral Mucositis Therapeutics Pipeline to Witness Many
Technological Advancements in the Coming Years
Chapter 6. Competitive Landscape
6.1 Key Players Benchmarking for Oral Mucositis Drug Candidates
6.2 SWOT Analysis of Oral Mucositis Pipeline
Chapter 7. Company Profiles
7.1 Daewoong Pharmaceutical Co., Ltd.
7.1.1 Business overview
7.1.2 Product and service offerings
7.2 Novartis AG
7.2.1 Business overview
7.2.2 Product and service offerings
7.3 Galera Therapeutics, Inc.
7.3.1 Business overview
7.3.2 Product and service offerings
7.4 Aldeyra Therapeutics, Inc.
7.4.1 Business overview
7.4.2 Product and service offerings
7.5 Cellceutix Corporation
7.5.1 Business overview
7.5.2 Product and service offerings
7.6 Oragenics, Inc.
7.6.1 Business overview
7.6.2 Product and service offerings
7.7 Soligenix, Inc.
7.7.1 Business overview
7.7.2 Product and service offerings
7.8 CleveXel Pharma, S.A.S
© P&S Market Research. All rights reserved 7

8. Oral Mucositis Therapeutics Pipeline to Witness Many
Technological Advancements in the Coming Years
7.8.1 Business overview
7.8.2 Product and service offerings
7.9 Wellstat Therapeutics Corporation
7.9.1 Business overview
7.9.2 Product and service offerings
Chapter 8. Appendix
8.1 Abbreviations
Browse Other Related Report at: https://www.psmarketresearch.com/industry-
report/pharmaceuticals
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for
various geographies around the globe. We provide market research reports, industry forecasting reports,
business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate
forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through
their interaction with leading companies of the concerned domain. We help our clients with B2B market research
and assist them in identifying various windows of opportunity, and framing informed and customized business
expansion strategies in different regions.
Contact:
Kundan
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
© P&S Market Research. All rights reserved 8